|Bid||0.7808 x 1400|
|Ask||0.7816 x 1200|
|Day's Range||0.7700 - 0.7900|
|52 Week Range||0.5000 - 1.3900|
|Beta (5Y Monthly)||1.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 06, 2023 - Nov 10, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.83|
One in eight women will be diagnosed with breast cancer during their lifetime. However, breast cancer does not affect all women in the same way, and individual physiology plays a huge factor. Women with dense breast tissue face a higher risk of developing breast cancer and being diagnosed with later-stage disease.
SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023. Details of the company's participation are as follows: Cantor Fitzgerald Global Healthcare Conference 2023Format: Fireside Chat with
Atossa Therapeutics (NASDAQ:ATOS) President & CEO Dr. Steven Quay joins Thomas Warner from Proactive to speak about the latest developments in his and the clinical-stage biopharma company's fight a...